Temporal trends of time in therapeutic range and incidence of cardiovascular events in patients with non-valvular atrial fibrillation

被引:21
作者
Pastori, Daniele [1 ,2 ]
Farcomeni, Alessio [3 ]
Saliola, Mirella [1 ]
Del Sole, Francesco [1 ]
Pignatelli, Pasquale [1 ]
Violi, Francesco [1 ]
Lip, Gregory Y. H. [2 ,4 ]
机构
[1] Sapienza Univ Rome, Dept Internal Med & Med Specialties, Clin Med 1, Atherothrombosis Ctr, Rome, Italy
[2] Univ Birmingham, Inst Cardiovasc Sci, Birmingham, W Midlands, England
[3] Sapienza Univ Rome, Dept Publ Hlth & Infect Dis, Rome, Italy
[4] Aalborg Univ, Dept Clin Med, Aalborg Thrombosis Res Unit, Aalborg, Denmark
关键词
Atrial fibrillation; Anticoagulation; Vitamin K antagonists; Time in therapeutic range; Cardiovascular events; PROTON PUMP INHIBITORS; ANTICOAGULATION CONTROL; ORAL ANTICOAGULATION; WARFARIN; QUALITY; RISK; EFFICACY; ASPIRIN; STROKE; SAFETY;
D O I
10.1016/j.ejim.2018.04.007
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Optimal time in therapeutic range (TTR) of vitamin K antagonists (VKAs) is crucial for cardiovascular events (CVEs) prevention in non-valvular atrial fibrillation (NVAF). The relationship between temporal changes of TTR and the incidence of CVEs has been poorly investigated. We investigated 1) temporal trends of TTR in a long-term follow-up of NVAF patients; 2) the incidence of CVEs according to changes of TTR. Methods: Prospective observational study including 1341 NVAF outpatients (mean age 73.5 years, 42.5% male) starting VKAs. Patients were divided into 4 groups: Group 0: Optimal TTR, consistently >= 70% (n = 241); Group 1: Temporally worsening TTR, from above to below 70% (n = 263); Group 2: Temporally improving TTR, from below to above 70% (n = 270); Group 3: Suboptimal TTR, consistently < 70% (n = 567). Results: In a mean follow-up of 37.7 months (4214.2 patient-years), 108 CVEs occurred (2.6%/year). Survival analysis showed a graded increased risk of CVEs in relation to temporal changes in TTR, with the worst outcomes in Groups 1 and 3 (log-rank test p = 0.013). Multivariable Cox proportional hazards regression analysis showed that Group 1 vs. 0 (HR: 2.096; 95%CI 1.061-4.139, p = 0.033), Group 3 vs. 0 (HR: 2.292; 95%CI 1.205-4.361, p = 0.011), CHA(2)DS(2)VASc score (HR:1.316; 95%CI 1.153-1.501, p < 0.001) and PPIs (HR:0.453; 95%CI 0.285-0.721, p = 0.001) were independently associated with CVEs. Conclusion: A decrease of TTR < 70% over time is observed in almost 20% of NVAF patients. Patients with worsening TTR temporally (ie. from initially above 70% to below 70%) have similar risk of CVEs of patients with consistently suboptimal anticoagulation.
引用
收藏
页码:34 / 39
页数:6
相关论文
共 32 条
  • [1] Anguita Sanchez M, 2015, REV ESP CARDIOL, V68, P761, DOI [10.1016/j.rec.2014.11.019, DOI 10.1016/J.REC.2014.11.019]
  • [2] Factors Affecting Quality of Anticoagulation Control Among Patients With Atrial Fibrillation on Warfarin The SAMe-TT2R2 Score
    Apostolakis, Stavros
    Sullivan, Renee M.
    Olshansky, Brian
    Lip, Gregory Y. H.
    [J]. CHEST, 2013, 144 (05) : 1555 - 1563
  • [3] Quality of Anticoagulation With Vitamin K Antagonists
    Bertomeu-Gonzalez, Vicente
    Anguita, Manuel
    Moreno-Arribas, Jose
    Cequier, Angel
    Muniz, Javier
    Castillo-Castillo, Jesus
    Sanchis, Juan
    Roldan, Inmaculada
    Marin, Francisco
    Bertomeu-Martinez, Vicente
    [J]. CLINICAL CARDIOLOGY, 2015, 38 (06) : 357 - 364
  • [4] Time in Therapeutic Range and Percentage of International Normalized Ratio in the Therapeutic Range as a Measure of Quality of Anticoagulation Control in Patients With Atrial Fibrillation
    Chan, Pak-Hei
    Li, Wen-Hua
    Hai, Jo-Jo
    Chan, Esther W.
    Wong, Ian C. K.
    Tse, Hung-Fat
    Lip, Gregory Y. H.
    Siu, Chung-Wah
    [J]. CANADIAN JOURNAL OF CARDIOLOGY, 2016, 32 (10) : 1247.e23 - 1247.e28
  • [5] Risk of Bleeding and Stroke with Oral Anticoagulation and Antiplatelet Therapy in Patients with Atrial Fibrillation in Taiwan: A Nationwide Cohort Study
    Chen, Pei-Chun
    Lip, Gregory Y. H.
    Yeh, Grace
    Lin, Hung-Ju
    Chien, Kuo-Liong
    [J]. PLOS ONE, 2015, 10 (04):
  • [6] Benefit of Oral Anticoagulant Over Antiplatelet Therapy in Atrial Fibrillation Depends on the Quality of International Normalized Ratio Control Achieved by Centers and Countries as Measured by Time in Therapeutic Range
    Connolly, Stuart J.
    Pogue, Janice
    Eikelboom, John
    Flaker, Gregory
    Commerford, Patrick
    Franzosi, Maria Grazia
    Healey, Jeffrey S.
    Yusuf, Salim
    [J]. CIRCULATION, 2008, 118 (20) : 2029 - 2037
  • [7] Efficacy and Safety of Proton Pump Inhibitors in the Long-Term Aspirin Users: A Meta-Analysis of Randomized Controlled Trials
    Dahal, Khagendra
    Sharma, Sharan P.
    Kaur, Jaspreet
    Anderson, Billie J.
    Singh, Gurpinder
    [J]. AMERICAN JOURNAL OF THERAPEUTICS, 2017, 24 (05) : E559 - E569
  • [8] Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis?
    Gallagher, A. M.
    Rietbrock, S.
    Plumb, J.
    van Staa, T. P.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2008, 6 (09) : 1500 - 1506
  • [9] Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation
    Gallego, Pilar
    Roldan, Vanessa
    Marin, Francisco
    Romera, Marta
    Valdes, Mariano
    Vicente, Vicente
    Lip, Gregory Y. H.
    [J]. THROMBOSIS AND HAEMOSTASIS, 2013, 110 (06) : 1189 - 1198
  • [10] Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry
    Haas, Sylvia
    ten Cate, Hugo
    Accetta, Gabriele
    Angchaisuksiri, Pantep
    Bassand, Jean-Pierre
    Camm, A. John
    Corbalan, Ramon
    Darius, Harald
    Fitzmaurice, David A.
    Goldhaber, Samuel Z.
    Goto, Shinya
    Jacobson, Barry
    Kayani, Gloria
    Mantovani, Lorenzo G.
    Misselwitz, Frank
    Pieper, Karen
    Schellong, Sebastian M.
    Stepinska, Janina
    Turpie, Alexander G. G.
    van Eickels, Martin
    Kakkar, Ajay K.
    Lucas Luciardi, Hector
    Gibbs, Harry
    Brodmann, Marianne
    Cools, Frank
    Pereira Barretto, Antonio Carlos
    Connolly, Stuart J.
    Spyropoulos, Alex
    Eikelboom, John
    Hu, Dayi
    Jansky, Petr
    Nielsen, Jorn Dalsgaard
    Ragy, Hany
    Raatikainen, Pekka
    Le Heuzey, Jean-Yves
    Keltai, Matyas
    Kakkar, Sanjay
    Sawhney, Jitendra Pal Singh
    Agnelli, Giancarlo
    Ambrosio, Giuseppe
    Koretsune, Yukihiro
    Sanchez Diaz, Carlos Jerjes
    Atar, Dan
    Panchenko, Elizaveta
    Lim, Toon Wei
    Oh, Seil
    Vinolas, Xavier
    Rosenqvist, Marten
    Steffel, Jan
    Oto, Ali
    [J]. PLOS ONE, 2016, 11 (10):